CN119013396A - 增强过继性细胞转移免疫疗法的方法 - Google Patents

增强过继性细胞转移免疫疗法的方法 Download PDF

Info

Publication number
CN119013396A
CN119013396A CN202280088910.2A CN202280088910A CN119013396A CN 119013396 A CN119013396 A CN 119013396A CN 202280088910 A CN202280088910 A CN 202280088910A CN 119013396 A CN119013396 A CN 119013396A
Authority
CN
China
Prior art keywords
igg
cells
protein
car
cell transfer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202280088910.2A
Other languages
English (en)
Chinese (zh)
Inventor
拉古韦尔·兰加纳坦
罗伯特·博克曼
安娜·卡琳·罗伯逊
克里斯蒂安·凯尔曼
詹彼得罗·多蒂
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Lufthansa Biopharmaceutical Co ltd
Original Assignee
Lufthansa Biopharmaceutical Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lufthansa Biopharmaceutical Co ltd filed Critical Lufthansa Biopharmaceutical Co ltd
Publication of CN119013396A publication Critical patent/CN119013396A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/52—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from bacteria or Archaea
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4873—Cysteine endopeptidases (3.4.22), e.g. stem bromelain, papain, ficin, cathepsin H
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/52—Genes encoding for enzymes or proenzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
    • C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01096—Mannosyl-glycoprotein endo-beta-N-acetylglucosaminidase (3.2.1.96)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01169—Protein O-GlcNAcase (3.2.1.169)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/22—Cysteine endopeptidases (3.4.22)
    • C12Y304/2201—Streptopain (3.4.22.10)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN202280088910.2A 2021-11-15 2022-11-14 增强过继性细胞转移免疫疗法的方法 Pending CN119013396A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163279398P 2021-11-15 2021-11-15
US63/279,398 2021-11-15
PCT/EP2022/081841 WO2023084095A2 (en) 2021-11-15 2022-11-14 Methods for enhancing adoptive cell transfer immunotherapies

Publications (1)

Publication Number Publication Date
CN119013396A true CN119013396A (zh) 2024-11-22

Family

ID=84463039

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202280088910.2A Pending CN119013396A (zh) 2021-11-15 2022-11-14 增强过继性细胞转移免疫疗法的方法

Country Status (7)

Country Link
US (1) US20250325640A1 (https=)
EP (1) EP4433587A2 (https=)
JP (1) JP2024544565A (https=)
CN (1) CN119013396A (https=)
AU (1) AU2022385450A1 (https=)
CA (1) CA3237815A1 (https=)
WO (1) WO2023084095A2 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN120334552A (zh) * 2025-06-12 2025-07-18 成都蓉生药业有限责任公司 一种人免疫球蛋白对非人种属细胞的adcp活性的检测试剂的组合、检测试剂盒及其检测方法

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025014862A1 (en) * 2023-07-07 2025-01-16 Emory University Recombinant glycosidases, pharmaceutical compositions, and uses in managing autoimmune or inflammatory conditions
WO2025030053A1 (en) * 2023-08-01 2025-02-06 Insmed Incorporated Novel igg proteases and methods of use thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201413240D0 (en) 2014-07-25 2014-09-10 Hansa Medical Ab Method
GB201502305D0 (en) 2015-02-12 2015-04-01 Hansa Medical Ab Protein
GB201502306D0 (en) 2015-02-12 2015-04-01 Hansa Medical Ab Protein
CN114450397A (zh) * 2019-08-01 2022-05-06 纪念斯隆-凯特琳癌症中心 用于改善免疫疗法的细胞及其用途
GB202007434D0 (en) * 2020-05-19 2020-07-01 Hansa Biopharma AB Methods

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN120334552A (zh) * 2025-06-12 2025-07-18 成都蓉生药业有限责任公司 一种人免疫球蛋白对非人种属细胞的adcp活性的检测试剂的组合、检测试剂盒及其检测方法
CN120334552B (zh) * 2025-06-12 2025-09-12 成都蓉生药业有限责任公司 一种人免疫球蛋白对非人种属细胞的adcp活性的检测试剂的组合、检测试剂盒及其检测方法

Also Published As

Publication number Publication date
JP2024544565A (ja) 2024-12-03
WO2023084095A3 (en) 2023-07-20
CA3237815A1 (en) 2023-05-19
WO2023084095A2 (en) 2023-05-19
AU2022385450A1 (en) 2024-06-13
US20250325640A1 (en) 2025-10-23
EP4433587A2 (en) 2024-09-25

Similar Documents

Publication Publication Date Title
EP3153526B1 (en) Antibodies against human cd39 and use thereof for inhibiting t regulatory cells activity
EP2946791B1 (en) Anti-CD277 antibodies and uses thereof
Kuwana et al. The role of autoreactive T-cells in the pathogenesis of idiopathic thrombocytopenic purpura
CN119013396A (zh) 增强过继性细胞转移免疫疗法的方法
JP7819119B2 (ja) 養子細胞移入免疫療法を増強する方法
EP4209503A1 (en) Il-2 mutant and application thereof
CN108884140A (zh) 修饰的嵌合受体及相关组合物和方法
CN112469479A (zh) 治疗癌症和自身免疫性疾病的试剂和方法
US20150368316A1 (en) A selective high-affinity immune stimulatory reagent and uses thereof
CN112004832A (zh) 结合cd83的嵌合抗原受体
US20260001961A1 (en) Novel polypeptides
US20250064855A1 (en) Use of dual-target CAR-T cells in treating B-cell autoimmune diseases
JP2026048806A (ja) 細胞傷害性ｔ細胞耐性腫瘍を治療するための組成物および方法
US20240374719A1 (en) Novel combinations of antibodies and uses thereof
JP2022544580A (ja) 骨髄性悪性腫瘍を処置するためのキメラ抗原受容体
CN115925945A (zh) 抗tigit人源化抗体或其抗原结合片段及其应用
US20240350630A1 (en) Compositions and methods of treating disease with chimeric antigen receptors to b cell maturation antigen (bcma)
Solomon Targeting regulatory T cells for therapeutic gain in cancer therapy
CN118434767A (zh) 新型多肽
KR20260052102A (ko) B 세포 자가면역 질환 치료에서 이중 표적 car-t 세포의 용도
HK40045337A (en) Methods and compositions for adoptive cell therapy
CN117295761A (zh) 与sars-cov-2刺突蛋白的受体结合结构域偶联或融合的抗体以及其用于疫苗目的的用途

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination